Gender-affirming hormone therapy may not increase CVD risk for transgender adolescents
DALLAS, May 20, 2021 — Transgender adolescents are more likely to have at least one cardiovascular disease risk factor compared to cisgender (same gender as at birth) adolescents, according to preliminary research to be presented at the American Heart Association’s Epidemiology, Prevention, Lifestyle & Cardiometabolic Health Conference 2021. The meeting is virtual, May 20-21 and offers the latest science on population-based health and wellness and implications for lifestyle.
The United States has a growing population of transgender adolescents ages 12-21 who seek medical transition gender-affirming hormone therapy. Gender-affirming hormone therapy involves taking estrogen or testosterone ...









